Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: Prognostic factors associated with clinical outcomes

Maartje G. Schouwenburg, Anouk Jochems, Brenda Leeneman, Margreet G. Franken, Alfons J. M. van den Eertwegh, John B. A. G. Haanen, Michiel C. T. van Zeijl, Maureen J. Aarts, Alexander C. J. van Akkooi, Franchette W. P. J. van den Berkmortel, Willeke A. M. Blokx, Jan Willem B. de Groot, Geke A. P. Hospers, Ellen Kapiteijn, Rutger H. Koornstra, Wim H. Kruit, Marieke W. J. Louwman, Djura Piersma, Rozemarijn S. van Rijn, Karijn P. M. SuijkerbuijkAlbert J. ten Tije, Gerard Vreugdenhil, Michel W. J. M. Wouters, Jacobus J. M. van der Hoeven

Research output: Contribution to journalArticleAcademicpeer-review

8 Citations (Scopus)


The aim of this population-based study was to identify the factors associated with clinical outcomes in vemurafenib-Treated patients and to evaluate outcomes across subgroups of patients with different risk profiles. Data were retrieved from the Dutch Melanoma Treatment Registry. Time to next treatment (TTNT) and overall survival (OS) of all metastatic melanoma patients who received vemurafenib between 2012 and 2015 were assessed using Kaplan-Meier estimates. A risk score was developed on the basis of all prognostic factors associated with TTNT and OS derived from multivariable Cox regression analyses. Patients were stratified according to the presence of prognostic risk factors by counting the number of factors, ranging from 0 to 6. A total of 626 patients received vemurafenib with a median follow-up of 35.8 months. The median TTNT and OS were 4.7 months [95% confidence intervals (CI): 4.4-5.1] and 7.3 months (95% CI: 6.6-8.0). The strongest prognostic factors were serum lactate dehydrogenase (LDH) level, Eastern Cooperative Oncology Group performance score, number of organ sites involved and brain metastases. Patients with a favourable risk profile (no risk factors) had a median TTNT and OS of 7.1 (95% CI: 5.8-8.5) and 15.4 months (95% CI: 10.0-20.9). The median OS more than halved for patients with greater than or equal to 2 risk factors compared with patients with no risk factors. The clinical outcomes of vemurafenib in metastatic melanoma patients with a favourable risk profile are comparable with the results of the trials. Combining prognostic factors into a risk score could be valuable to stratify patients into favourable and poor-prognosis groups.
Original languageEnglish
Pages (from-to)326-332
JournalMelanoma Research
Issue number4
Publication statusPublished - 2018

Cite this